| Literature DB >> 28193599 |
Laura R Saslow1, Ashley E Mason2, Sarah Kim3, Veronica Goldman2, Robert Ploutz-Snyder4, Hovig Bayandorian5, Jennifer Daubenmier6, Frederick M Hecht2, Judith T Moskowitz7.
Abstract
BACKGROUND: Type 2 diabetes is a prevalent, chronic disease for which diet is an integral aspect of treatment. In our previous trial, we found that recommendations to follow a very low-carbohydrate ketogenic diet and to change lifestyle factors (physical activity, sleep, positive affect, mindfulness) helped overweight people with type 2 diabetes or prediabetes improve glycemic control and lose weight. This was an in-person intervention, which could be a barrier for people without the time, flexibility, transportation, social support, and/or financial resources to attend.Entities:
Keywords: diet; eHealth; type 2 diabetes mellitus; weight loss
Mesh:
Substances:
Year: 2017 PMID: 28193599 PMCID: PMC5329646 DOI: 10.2196/jmir.5806
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Study participant flowchart for online study.
Baseline participant characteristics (N=25).
| Baseline characteristics | Intervention group (n=12) | Control group (n=13) | |
| Male | 6 (50) | 4 (31) | |
| Female | 6 (50) | 9 (69) | |
| Age (years), mean (SD) | 53.0 (10.2) | 58.2 (6.7) | |
| Asian/Pacific Islander | 2 (17) | 2 (15) | |
| Black | 3 (25) | 0 (0) | |
| White | 7 (58) | 8 (62) | |
| Latino/a | 2 (17) | 5 (38) | |
| Duration of diabetes (years), mean (SD) | 5.3 (4.1) | 5.7 (3.7) | |
| HbA1c (%), mean (SD) | 7.1 (0.4) | 7.2 (0.3) | |
| Weight (kg), mean (SD) | 109.7 (24.9) | 90.9 (16.4) | |
| Triglycerides (mg/dL), mean (SD) | 174.1 (79.4) | 151.5 (87.1) | |
| HDL cholesterol (mg/dL), mean (SD) | 45.7 (15.0) | 53.9 (12.7) | |
| LDL cholesterol (mg/dL), mean (SD) | 96.9 (30.4) | 90.5 (29.0) | |
| Diabetes-related distress, mean (SD) | 1.9 (0.8) | 2.4 (1.2) | |
| CES-Depression, mean (SD) | 10.5 (7.7) | 9.8 (7.4) | |
| CES-D Positive Affect, mean (SD) | 10.2 (2.3) | 10.2 (2.2) | |
| DES Negative Affect, mean (SD) | 2.8 (1.3) | 2.7 (1.4) | |
| DES Positive Affect, mean (SD) | 6.5 (1.1) | 6.2 (1.5) | |
| Vitality (SF-36 subscale), mean (SD) | 53.3 (16.4) | 49.2 (20.1) | |
| Total kilocalories, mean (SD) | 1768.5 (626.6) | 1749.1 (322.2) | |
| Total grams of nonfiber carbohydrates, mean (SD) | 163.6 (86.7) | 152.0 (58.9) | |
| Total grams of fat, mean (SD) | 77.1 (41.4) | 81.3 (27.3) | |
| Total grams of protein, mean (SD) | 83.3 (18.0) | 74.5 (17.2) | |
| Total grams of sugar, mean (SD) | 50.6 (33.8) | 44.9 (23.8) | |
Estimated marginal mean (EMM) changes from baseline to 16 and 32 weeks.a
| Outcomes | Intervention group, EMM (95% CI)b | Control group, EMM (95% CI)c | Difference between groups, EMM (95% CI) | ||
| 16 weeks | –0.9 (–1.1, –0.6) | –0.5 (–0.8, –0.2) | –0.4 (–0.7, –0.1) | .01 | |
| 32 weeks | –0.8 (–1.1, –0.6) | –0.3 (–0.6, 0.0) | –0.5 (–0.8, –0.2) | .002 | |
| 16 weeks | –8.5 (–11.9, –5.2) | –3.9 (–8.0, 0.2) | –4.6 (–8.8, –0.4) | .03 | |
| 32 weeks | –12.7 (–16.1, –9.2) | –3.0 (–7.3, 1.3) | –9.6 (–14.0, –5.3) | <.001 | |
| 16 weeks | –35.5 (–65.7, –5.2) | –17.4 (–55.2, 20.4) | –18.1 (–56.1, 19.9) | .35 | |
| 32 weeks | –60.1 (–91.3, –28.9) | –6.2 (–46.0, 33.6) | –53.9 (–93.6, –14.2) | .01 | |
| 16 weeks | 1.4 (–2.7, 5.6) | –0.3 (–5.3, 4.8) | 1.7 (–3.4, 6.8) | .52 | |
| 32 weeks | 4.8 (0.5, 9.1) | 0.6 (–4.7, 5.9) | 4.1 (–1.2, 9.5) | .13 | |
| 16 weeks | –0.8 (–10.9, 9.4) | 1.5 (–11.7, 14.7) | –2.2 (–15.3, 10.8) | .74 | |
| 32 weeks | –0.3 (–10.8, 10.3) | –6.1 (–19.9, 7.7) | 5.9 (–7.8, 19.5) | .40 | |
| 16 weeks | –0.5 (–0.8, –0.1) | –0.3 (–0.7, 0.1) | –0.1 (–0.6, 0.3) | .49 | |
| 32 weeks | –0.4 (–0.8, 0.0) | –0.4 (–0.8, 0.0) | 0.0 (–0.5, 0.5) | .98 | |
| 16 weeks | –3.7 (–7.8, 0.5) | 0.8 (–3.7, 5.4) | –4.5 (–9.3, 0.4) | .07 | |
| 32 weeks | –0.6 (–5.0, 3.7) | –1.0 (–6.0, 4.0) | –0.4 (–4.8, 5.6) | .88 | |
| 16 weeks | 8.4 (–5.3, 22.2) | –4.4 (–19.1, 10.3) | 12.9 (–2.9, 28.7) | .11 | |
| 32 weeks | 0.5 (–13.6, 14.8) | 7.2 (–9.0, 23.4) | –6.6 (–23.5, 10.3) | .45 | |
| 16 weeks | –0.7 (1.5, 0.1) | –0.1 (–0.9, 0.8) | –0.6 (–1.5, 0.3) | .19 | |
| 32 weeks | –0.4 (–1.2, 0.4) | –0.7 (–1.6, 0.2) | 0.3 (0.5, –0.6) | .49 | |
| 16 weeks | 0.5 (–0.3, 1.4) | –0.2 (–1.1, 0.7) | 0.7 (–0.3, 1.7) | .15 | |
| 32 weeks | 0.4 (–0.5, 1.2) | 0.3 (–0.7, 1.2) | 0.1 (–0.9, 1.1) | .82 | |
| 16 weeks | 13.3 (2.5, 24.02) | 2.3 (–9.4, 13.9) | 11.0 (–1.4, 23.4) | .08 | |
| 32 weeks | 9.2 (–1.9, 20.4) | 11.0 (–1.8, 23.8) | –1.8 (–15.1, 11.6) | .80 | |
| 16 weeks | –362.9 (–634.7, –91.1) | –300.8 (–594.3, –7.4) | –62.1 (–376.0, 251.7) | .65 | |
| 32 weeks | –439.3 (–719.4, –159.3) | –216.6 (–559.2, 125.9) | –222.7 (–569.9, 124.5) | .13 | |
| 16 weeks | –123.2 (–167.2, –79.2) | –27.03 (–75.4, 21.3) | –19.2 (–147.4, –44.9) | <.001 | |
| 32 weeks | –122.7 (–167.9, –77.5) | –14.8 (–71.0, 41.5) | –107.9 (–164.6, –51.3) | <.001 | |
| 16 weeks | –7.8 (–36.3, 20.7) | –18.7 (–48.8, 11.4) | 10.9 (–21.7, 43.4). | .42 | |
| 32 weeks | –4.0 (–33.2, 25.3) | –23.7 (–58.5, 11.1) | 19.8 (–15.9, 55.5) | .13 | |
| 16 weeks | –0.5 (–14.0, 13.0) | –0.2 (–15.3, 14.9) | –0.3 (–16.2, 15.6) | .97 | |
| 32 weeks | –1.6 (–15.5, 12.3) | –0.1 (–17.7, 17.6) | –1.5 (–19.2, 16.1) | .86 | |
| 16 weeks | –37.2 (–53.8, –20.5) | –4.4 (–22.9, 14.1) | –32.7 (–52.3, –13.2) | <.001 | |
| 32 weeks | –32.5 (–49.7, –15.4) | –0.3 (–21.9, 21.3) | –32.2 (–53.9, –10.6) | <.001 | |
a Data are estimated marginal means and 95% confidence intervals by linear mixed-effects model analysis.
b Total analyzed in intervention group: n=12 for week 16 and n=11 for week 32.
c Total analyzed in control group: n=9 for week 16 and n=8 for week 32.
Figure 2Mean and individual body weight (in kilograms) for the intervention and control groups at baseline and at 16 and 32 weeks. Bars represent 95% confidence intervals of the mean. Dashed lines reflect individual participants; darker lines represent each group mean.
Percentage of people meeting HbA1c and weight change thresholds.
| HbA1c and weight outcomes | Intervention groupa | Control groupb | Difference between groups | ||
| 16 weeks | 9 (75%) | 1 (13%) | .02 | ||
| 32 weeks | 6 (55%) | 0 (0%) | .02 | ||
| 16 weeks | –7.8 (3.6) | –4.2 (3.7) | –3.6 (–7.1, –0.1) | .04 | |
| 32 weeks | –12.0 (7.3) | –2.5 (4.6) | –9.5 (–16.1, –2.9) | .01 | |
| 16 weeks | 10 (83%) | 3 (38%) | .06 | ||
| 32 weeks | 10 (90%) | 2 (29%) | .01 | ||
a Total in intervention group: n=12 at 16 weeks and n=11 at 32 weeks.
b Total in control group: n=8 at 16 weeks and n=8 at 32 weeks for participants with HbA1c <6.5%, and n=7 at 32 weeks for participants achieving a 5% weight loss.
Figure 3Mean and individual body weight (in kilograms) for the intervention and control groups at baseline and at 16 and 32 weeks. Bars represent 95% confidence intervals of the mean. Dashed lines reflect individual participants; darker lines represent each group mean.
Figure 4Body weight and HbA1c plotted for each participant separately for each of the three time periods (0, 16, and 32 weeks). Red lines represent the intervention participants; blue lines represent the control participants. Lines that end in an O reflect dropouts (and missing data). Lines that end in an arrow show participants who completed the study.
Self-reported ratings of subjective experience of the diets.
| Self-reported ratings | Intervention group, mean (SD) | Control group, mean (SD) | Cohen | |
| 16 weeks | 5.9 (1.1) | 5.2 (1.3) | 0.6 | |
| 32 weeks | 6.2 (1.0) | 4.9 (2.3) | 0.8 | |
| 16 weeks | 6.2 (1.0) | 5.3 (1.8) | 0.6 | |
| 32 weeks | 6.2 (0.9) | 5.1 (2.5) | 0.5 | |
| 16 weeks | 2.7 (1.4) | 3.9 (0.9) | –1.0 | |
| 32 weeks | 3.4 (1.1) | 5.0 (0.8) | –1.7 | |
| 16 weeks | 2.7 (1.5) | 4.0 (1.3) | –0.9 | |
| 32 weeks | 3.2 (1.5) | 4.0 (1.7) | –0.5 | |